10 results on '"Janssen, Jeroen J. W. M."'
Search Results
2. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
- Author
-
Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M, Silzle T, van Lammeren-Venema D, Moors I, Breems DA, Hoogendoorn M, Legdeur MJC, Fischer T, Kuball J, Cornelissen J, Porkka K, Juliusson G, Meyer P, Höglund M, Gjertsen BT, Janssen JJWM, Huls G, Passweg J, Cloos J, Valk PJM, van Elssen CHMJ, Manz MG, Floisand Y, and Ossenkoppele GJ
- Subjects
- Adolescent, Adult, Aged, Humans, Lenalidomide, Middle Aged, Remission Induction, Transplantation, Autologous, Young Adult, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy
- Abstract
Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% ± 2% standard error and overall survival, 54% ± 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
3. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile.
- Author
-
van der Wagen LE, Miranda-Bedate A, Janssen A, Fernando F, Appukudige N, van Dooremalen S, Westinga K, Admiraal R, Lorenowicz MJ, Huls G, Janssen JJWM, Broers AEC, van der Velden WJFM, van Marwijk Kooy R, Hazenberg MD, de Haar C, Lindemans C, Jan Boelens J, and Kuball J
- Subjects
- Acute Disease, Humans, Steroids, Tissue Donors, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells
- Published
- 2020
- Full Text
- View/download PDF
4. Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies.
- Author
-
de Jong G, Janssen JJWM, Biemond BJ, Zeerleder SS, Ossenkoppele GJ, Visser O, Nur E, Meijer E, and Hazenberg MD
- Subjects
- Adolescent, Adult, Aged, Allografts, Disease-Free Survival, Female, Humans, Male, Middle Aged, Recurrence, Retrospective Studies, Survival Rate, Cytarabine administration & dosage, Hematologic Neoplasms mortality, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation, Lymphocyte Transfusion, Myeloproliferative Disorders mortality, Myeloproliferative Disorders therapy
- Abstract
Objective: Relapse of AML after allogeneic hematopoietic stem cell transplantation (HSCT) has a poor prognosis, and standard of care therapy is lacking. Early (<6 months) relapse is associated with dismal outcome, while the majority of relapses occur early after transplantation. A more precise indication which patients could benefit from reinduction therapy is warranted., Methods: We retrospectively analyzed outcomes of 83 patients with postallogeneic HSCT relapse. Patients were divided based on intention to treat (curative vs supportive care)., Results: Of the 50 patients treated with curative intent, 44% reached complete remission (CR) upon reinduction chemotherapy, and of these patients, 50% survived. Two survivors reached CR after immunotherapy (donor lymphocyte infusion (DLI), without reinduction chemotherapy). Sixty-nine percent of the survivors had received high-intensity cytarabine treatment, followed by immunologic consolidation. Relapse <3 months after transplantation was predictive for adverse survival (P = .004), but relapse <6 months was not. In fact, >50% of the survivors had a relapse <6 months., Conclusion: We confirmed the dismal prognosis of postallogeneic HSCT relapse. Importantly, our data demonstrate that patients fit enough to receive high-dose chemotherapy, even when relapse occurred <6 months, had the best chance to obtain durable remissions, in particular when immunologic consolidation was performed after reaching CR., (© 2019 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
5. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
- Author
-
Wilhelm AJ, de Graaf P, Veldkamp AI, Janssen JJ, Huijgens PC, and Swart EL
- Subjects
- Adolescent, Adult, Aged, Area Under Curve, Bayes Theorem, Biological Availability, Cyclosporine administration & dosage, Dose-Response Relationship, Drug, Drug Monitoring methods, Female, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Models, Biological, Prospective Studies, Sampling Studies, Transplantation, Homologous methods, Young Adult, Cyclosporine pharmacokinetics, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation methods, Immunosuppressive Agents pharmacokinetics
- Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The population pharmacokinetics and limited sampling strategies for ciclosporin monitoring have been extensively studied in renal and liver transplant recipients. Little is known about the pharmacokinetics of ciclosporin in patients undergoing haematopoietic allogeneic stem cell transplantation (HSCT). • It is anticipated that there is a difference in pharmacokinetics in patients after kidney or liver transplantation compared with patients undergoing stem cell transplantation, because of mucositis and interacting drugs (e.g. fluconazole). • Data on the pharmacokinetics of ciclosporin and the relationship between its systemic exposure, as reflected by the area under the curve (AUC), and the biological effect as graft vs. host-disease (GVHD) prophylaxis and graft vs. tumour (GVT) response are scarce in patients after HSCT. WHAT THIS STUDY ADDS • A pharmacokinetic model was developed for orally and intravenously administered ciclosporin, enabling an adequate estimate of the systemic exposure of ciclosporin in patients after HSCT. A limited sampling strategy was tested that may serve as a tool to study the optimum systemic exposure (AUC) of ciclosporin in HSCT to prevent GVHD but establish adequate GVT response and to guide therapeutic drug monitoring. AIM To develop a population pharmacokinetic model of ciclosporin (CsA) in haematopoietic allogeneic stem cell transplantation to facilitate a limited sampling strategy to determine systemic exposure (area under the curve [AUC]), in order to optimize CsA therapy in this patient population. METHODS The pharmacokinetics of CsA were investigated prospectively in 20 patients following allogeneic haematopoietic stem cell transplantation (HSCT). CsA was given twice daily, as a 3 h i.v. infusion starting at day 1 of the conditioning scheme, and orally later on, when oral intake was well tolerated. Fluconazole was given as antimycotic prophylaxis. Pharmacokinetic parameter estimation was performed using nonlinear mixed effect modelling as implemented in the NONMEM program. A first order absorption model with lag time was compared with Erlang frequency distribution and Weibull distribution models. The influence of demographic variables on the individual empirical Bayesian estimates of clearance and distribution volume was tested. Subsequently two limited sampling strategies (LSS) were evaluated: posterior Bayesian fitting and limited sampling equations. RESULTS Twenty patients were included and 435 samples were collected after i.v. and oral administration of CsA. A two compartment model with first order absorption best described the data. Clearance (CL) was 21.9 l h(-1) (relative standard deviation [RSD]± 5.2%) with an inter-individual variability of 21%. The central volume of distribution (V(c) ) was 18.3 l (RSD ± 8.7%) with an inter-individual variability of 29%. Bioavailability (F) was 0.71 (RSD ± 9.9%) with and inter-individual variability of 25% and lag time (t(lag) ) was 0.44 h (RSD 5.5%). Weight, body surface area, haematocrit, albumin, ALAT and ASAT had no significant influence on pharmacokinetic parameters. The best multiple point combination for posterior Bayesian fitting, in terms of estimating systemic CsA exposure, appeared to be C0 + C2 + C3. Two selected LSS two time point equations and all selected three and four time point equations predicted de all AUC(0,12 h) within 15% bias and prediction. CONCLUSIONS The i.v. and oralcurves were best described with a two compartment model with first-order absorption with lag time. With the Bayesian estimators from this model, the area under the concentration-time curve in HSCT patients taking fluconazole can be estimated with only three blood samples (0, 2, 3 h) with a bias of 1% and precision of 4%., (© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.)
- Published
- 2012
- Full Text
- View/download PDF
6. [Autologous stem cell transplantation in haematological disorders,1980-2002].
- Author
-
Beckers MM, Verdonck LF, Cornelissen JJ, Schattenberg AV, Janssen JJ, Willemze R, van Imhoff GW, van der Lelie JH, Wijermans P, Schaafsma R, Baars J, van Marwijk Kooij MR, Biesma DH, van Biezen A, Brand R, and Schouten HC
- Subjects
- Adolescent, Adult, Aged, Cohort Studies, Female, Humans, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Multiple Myeloma mortality, Multiple Myeloma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Registries, Retrospective Studies, Survival Rate, Transplantation, Autologous, Young Adult, Hematologic Diseases mortality, Hematologic Diseases therapy, Hematopoietic Stem Cell Transplantation statistics & numerical data
- Abstract
Objective: To describe activities in the field of autologous stem cell transplantation in haematological disorders in the Netherlands in the periods before and after 1993 (at that time blood was introduced as source of stem cells)., Design: Descriptive, retrospective cohort study., Method: Data were collected from the Netherlands Stem Cell Transplantation Registry TYPHON. Details of all transplant patients were reported to TYPHON by the individual transplantation centres. In this overview we describe the changes in transplantation-related mortality, relapse rates and survival in the periods 1 January 1980-31 December 1992 and 1 January 1980-31 December 2002., Results: The number of autologous stem cell transplantations increased almost five-fold in the period 1993-2002. Since 1993 the main indications for transplantation were multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), as well as acute myeloid leukaemia (AML), which was the main indication in the period before 1993. In the period before 1993 most relapses were observed in patients with acute lymphoblastic leukaemia (ALL) and MM, which resulted in low survival rates. After 1993 no great differences in relapse or survival rates were observed between the different disorders. The survival rates for patients with ALL improved during the last research period, especially among younger patients (< 45 years)., Conclusion: The number of autologous stem cell transplantations has increased considerably since 1993, especially in patients with MM and NHL.
- Published
- 2010
7. Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
- Author
-
de Leeuw, David C., Ossenkoppele, Gert J., and Janssen, Jeroen J. W. M.
- Published
- 2022
- Full Text
- View/download PDF
8. A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts.
- Author
-
Smilde, Bernard J., Botman, Esmée, de Vries, Teun J., de Vries, Ralph, Micha, Dimitra, Schoenmaker, Ton, Janssen, Jeroen J. W. M., and Eekhoff, Elisabeth M. W.
- Subjects
HEMATOPOIETIC stem cells ,ORGANS (Anatomy) ,HEMATOPOIETIC stem cell transplantation ,CELL differentiation ,FIBROBLASTS - Abstract
Fibroblasts have an important role in the maintenance of the extracellular matrix of connective tissues by producing and remodelling extracellular matrix proteins. They are indispensable for physiological processes, and as such also associate with many pathological conditions. In recent years, a number of studies have identified donor-derived fibroblasts in various tissues of bone marrow transplant recipients, while others could not replicate these findings. In this systematic review, we provide an overview of the current literature regarding the differentiation of hematopoietic stem cells into fibroblasts in various tissues. PubMed, Embase, and Web of Science (Core Collection) were systematically searched for original articles concerning fibroblast origin after hematopoietic stem cell transplantation in collaboration with a medical information specialist. Our search found 5421 studies, of which 151 were analysed for full-text analysis by two authors independently, resulting in the inclusion of 104 studies. Only studies in animals and humans, in which at least one marker was used for fibroblast identification, were included. The results were described per organ of fibroblast engraftment. We show that nearly all mouse and human organs show evidence of fibroblasts of hematopoietic stem cell transfer origin. Despite significant heterogeneity in the included studies, most demonstrate a significant presence of fibroblasts of hematopoietic lineage in non-hematopoietic tissues. This presence appears to increase after the occurrence of tissue damage. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
- Author
-
Kuijvenhoven, Marianne A., Wilhelm, Abraham J., Meijer, Ellen, Janssen, Jeroen J. W. M., and Swart, Eleonora L.
- Subjects
DRUG side effects ,ADULTS ,CYCLOSPORINE ,STEM cells ,DRUG monitoring - Abstract
Objective: To investigate the incidence and severity of adverse drug reactions of cyclosporine using AUC‐targeted therapeutic drug monitoring (TDM) compared to trough level (Ctrough)‐targeted TDM in adult allogeneic stem cell recipients. Methods: Blind, monocenter, intervention study. Subjects were 1:1 randomized into either an AUC group or a Ctrough group. Adverse drug reactions were accessed two and four weeks after start of treatment. Results: Forty patients were included, resulting in 15 evaluable subjects (AUC group) and 13 evaluable subjects (Ctrough group). Grade two/three toxicity was observed in 46% (Ctrough group) versus 60% of subjects (AUC group) (P =.463). There was no significant difference between two and four weeks after start of cyclosporine for nausea (P =.142 resp. P =.122), renal dysfunction (P =.464 resp. P = 1.000), and hypomagnesemia (P = 1.000 resp. P =.411). Subjects in the AUC group reached the therapeutic goal earlier (72,7% versus 43,0% at third sampling point, P =.332) and were within the target range more consistently. Conclusion: This study showed no reduction in incidence and severity of cyclosporine‐induced toxicity with AUC‐ versus trough level‐targeted TDM. Although modeled dosing based on AUC led to faster optimal target attainment, this did not result in less toxicity in the early days after transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy
- Author
-
Wilhelm, Abraham J, de Graaf, Peer, Veldkamp, Agnes I, Janssen, Jeroen J W M, Huijgens, Peter C, and Swart, Eleonora L
- Subjects
Male ,Cyclosporine ,Hematopoietic Stem Cell Transplantation ,Graft vs Host Disease ,Humans ,Pharmacokinetics ,Female ,Immunosuppressive Agents - Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.